Triple threat: new Pre-Surgery combo targets stomach cancer

NCT ID NCT07182565

Recruiting now Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether giving a shorter course of radiation (hypofractionated radiotherapy) along with immunotherapy (serplulimab) and chemotherapy before surgery can safely improve outcomes for people with gastroesophageal junction cancer. The trial will enroll 84 participants with locally advanced but resectable disease. The goal is to find the best radiation dose and see how many patients have no cancer left at the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hypofractionated radiotherapy, serplulimab (PD-1 inhibitor), paclitaxel, and TS-1
What this could lead to: If successful, this could offer a more effective pre-surgery treatment for gastroesophageal junction cancer, potentially increasing the chance of complete tumor removal and long-term control.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants (84). The combination may cause significant side effects, and it is not yet known if it will improve survival or cure rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA HYPOFRACTIONATED RADIOTHERAPY

Contacts and locations

Locations

The Seventh People's Hospital of Chengdu
RECRUITING

Chengdu, Sichuan, 610041, China
West China Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China
West China Shangjin Nanfu Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China
West China Xiamen Hospital, Sichuan University
RECRUITING

Xiamen, Fujian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.